This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Aug;11(4):195.

doi: 10.1016/j.clbc.2011.02.005. Epub 2011 May 18.

Fulvestrant high dose vs. loading dose vs. approved dose: have we found the optimum dose?

Angela Mae Obermiller¹, Mehmet Sitki Copur

Affiliations

PMID: 21729663
DOI: 10.1016/j.clbc.2011.02.005

Comment

Fulvestrant high dose vs. loading dose vs. approved dose: have we found the optimum dose?

Angela Mae Obermiller et al. Clin Breast Cancer. 2011 Aug.

. 2011 Aug;11(4):195.

doi: 10.1016/j.clbc.2011.02.005. Epub 2011 May 18.

Authors

Angela Mae Obermiller¹, Mehmet Sitki Copur

Affiliation

¹ Saint Francis Cancer Treatment Center, Medical Oncology, Grand Island, NE.

PMID: 21729663
DOI: 10.1016/j.clbc.2011.02.005

No abstract available

PubMed Disclaimer

Comment on

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M. Di Leo A, et al. J Clin Oncol. 2010 Oct 20;28(30):4594-600. doi: 10.1200/JCO.2010.28.8415. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855825 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources